SPGI vs ZYME · P/E 27, rev $15.34B vs rev $76.3M
S&P Global Inc (SPGI) versus Zymeworks Inc. Common Stock (ZYME) — a side-by-side from cached financials, not a winner call.
S&P Global Inc (SPGI) is a financial data & stock exchanges company listed on NYSE.
Zymeworks Inc. Common Stock (ZYME) is a biotechnology company listed on NASDAQ.
Latest reported SPGI revenue for 2025-12-31 was $15.34B. Net income was $4.47B. Revenue was up 7.9% from 2024-12-31 to 2025-12-31. SPGI currently screens at market cap $127.50B and trailing P/E 27.2.
Latest reported ZYME revenue for 2024-12-31 was $76.3M. Net income was -$122.7M. Revenue was up 0.4% from 2023-12-31 to 2024-12-31. ZYME currently screens at market cap $1.68B.
SPGI currently screens at market cap $127.50B and trailing P/E 27.2. ZYME currently screens at market cap $1.68B.
Not investment advice. Open the SPGI and ZYME stock pages for the full models.
Not investment advice.